2024 Award 3 Retouch
VasoDynamics Receives Global Health & Pharma Biotechnology 2024 Award

VasoDynamics receives Global Heath & Pharma Biotechnology Award 2024 as Best Cancer Care Solutions Provider 2024 – UK

10th April 2024 VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has received the Biotechnology 2024 Award from Global Health & Pharma (GHP) as Best Cancer Care Solutions Provider 2024- UK for their platform technology and pipeline pharmaceutical programmes targeting the prevention/reduction of anticancer therapies induced severe mouth ulceration (NG11), dermatitis (NG12), and hair-loss (NG13).

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“VasoDynamics, as the first and only UK biotech/biopharma company that is currently able to boast an innovative drug repositioning and repurposing technology platform, is pioneering the development of a range of pharmaceutical products for the prevention and reduction of debilitating side-effects including mouth ulceration, hair-loss and skin damage from anti-cancer therapeutics. We are pleased to see the progression of current NG11-2 clinical trial for the prevention/reduction of mouth ulceration during cancer radiotherapy and chemoradiotherapy, quoting our clinical research staff’s words – ‘we now have the patient eating steak & chips (during the course of radiotherapy) which was unheard of before’. We are delighted to have received the award from GHP for the second time in recognition of the impact of our platform technology, and remain committed to advancing our pipeline products development in further pivotal clinical trials.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.